Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation
Danhash, E. P.; Verbeck, A. C.; Western, D.; Diaz-Pacheco, A.; Galasso, G.; You, S.-F.; Nadarajah, C. J.; Tiemann-Powles, S.; Huang, G.; Musiek, E. S.; Herz, J.; Iyer, A. K.; Cirrito, J.; Cruchaga, C.; Karch, C. M.
Show abstract
Genome-wide association studies for Alzheimer disease (AD) risk have identified a number of genes enriched in microglia, including MS4A4A. Common variants in MS4A4A influence AD risk, MS4A4A expression, TREM2 signaling, and a specific microglial transcriptional state, though the exact role of MS4A4A in AD remains unclear. Using a mouse model of amyloid beta (A{beta}) accumulation (5xFAD), we examined the impact of Ms4a4a loss on A{beta} pathology. Before A{beta} accumulation, Ms4a4a loss reduces steady-state A{beta} levels and shortens A{beta} half-life in brain interstitial fluid. In aged 5xFAD Ms4a4a-deficient mice, plaques are more compact with reduced overall plaque burden. Microglia lacking Ms4a4a are more pro-inflammatory and produce more MMP-9, which may promote degradation of A{beta} and A{beta} fibrils. Human subjects that carry a variant near MS4A4A (rs1582763) that confers resilience to AD also exhibit significantly elevated levels of MMP-9 in their cerebrospinal fluid. Together, our results suggest that loss of Ms4a4a improves A{beta} pathology by altering A{beta} clearance, offering insights for therapeutic interventions in AD.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology 98%
- A Trem2*R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques 97%
- Amyloid plaque deposition accelerates tau propagation via activation of microglia in a humanized APP mouse model 97%
Similar papers in this journal
- C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimers disease 97%
- Divergent and Convergent TMEM106B Pathology in Murine Models of Neurodegeneration and Human Disease 96%
- Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer's disease. 96%
Similar papers in this journal
- Amelioration of symptomatic Alzheimer's Disease after selective impairment of p75NTR function in adult forebrainexcitatory neurons 96%
- Genetic mapping of APP and amyloid-β biology modulation by trisomy 21 96%
- Endothelial Cells are Heterogeneous in Different Brain Regions and are Dramatically Altered in Alzheimer's Disease 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.